AstraZeneca
$156.90Change from previous close: −0.51%Absolute change: −$0.80
At a glance
- Revenue growth
- +8.63%
- 2025 vs 2024
- Net income growth
- +45.34%
- 2025 vs 2024
- Net margin
- 17.4%
- 2024: 13.0%
Financial data
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 2,865 | 3,359 | 2,342 | 5,134 | 3,386 | 3,713 | 2,907 | 3,383 | 3,085 | 2,486 | 2,380 | 3,114 |
| Depreciation and amortization | 1,584 | 1,366 | 1,170 | 1,549 | 1,389 | 1,284 | 630 | 1,817 | 1,279 | 1,255 | 1,167 | 1,226 |
| Capital expenditure | -763 | -547 | -1,036 | -686 | -659 | -429 | -708 | -417 | -382 | -417 | -525 | -319 |
| Investing cash flow | -2,912 | -1,792 | -1,446 | -2,001 | -2,108 | -1,253 | -1,181 | -1,514 | -2,872 | -2,413 | -1,077 | -1,221 |
| Financing cash flow | -2,592 | 267 | -3,282 | -2,073 | 518 | -2,707 | -671 | -4,131 | -1,222 | 2,028 | -291 | -2,726 |
| Dividends paid | -1.0 | -3,287 | -3.0 | -1,611 | -10.0 | -3,347 | — | -1,576 | -17.0 | -3,033 | -2.0 | -1,410 |
| Share repurchases | -46.0 | -612 | -13.0 | -19.0 | -3.0 | -486 | 0.0 | -81.0 | — | — | — | — |
| Debt issued | -12.0 | 4,324 | -1,012 | -352 | 644 | 1,099 | -572 | -415 | 1,502 | 5,977 | 51.0 | 38.0 |
| Debt repaid | -2,539 | -96.0 | -2,108 | -93.0 | -115 | -85.0 | -119 | -2,087 | -2,712 | -81.0 | -361 | -1,312 |
| Effect of exchange rates | 9.0 | -18.0 | 4.0 | -12.0 | 29.0 | 25.0 | -61.0 | 20.0 | -6.0 | -46.0 | 6.0 | -19.0 |
| Net change in cash | -2,630 | 1,816 | -2,382 | 1,048 | 1,825 | -222 | 994 | -2,242 | -1,015 | 2,055 | 1,018 | -852 |
| Free cash flow | 2,102 | 2,812 | 1,306 | 4,448 | 2,727 | 3,284 | 2,199 | 2,966 | 2,703 | 2,069 | 1,855 | 2,795 |
| Levered free cash flow | 227 | 821 | 1,205 | 2,804 | 1,617 | 2,128 | 3,289 | 1,797 | 1,984 | 1,360 | 3,413 | 2,343 |